{"id":"https://openalex.org/W7223674945","doi":"https://doi.org/10.32604/or.2026.088774","title":"Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer","display_name":"Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer","publication_year":2026,"publication_date":"2026-01-01","ids":{"openalex":"https://openalex.org/W7223674945","doi":"https://doi.org/10.32604/or.2026.088774","pmid":"https://pubmed.ncbi.nlm.nih.gov/42985504","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13732342"},"language":"en","primary_location":{"id":"doi:10.32604/or.2026.088774","doi":"https://doi.org/10.32604/or.2026.088774","is_oa":true,"landing_page_url":"https://doi.org/10.32604/or.2026.088774","pdf_url":"https://www.techscience.com/or/online/detail/28777/TSP_OR_88774.pdf","source":{"id":"https://openalex.org/S146643948","display_name":"Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics","issn_l":"0965-0407","issn":["0965-0407","1555-3906"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","medline","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4360969325","host_organization_name":"Cognizant Communication Corporation","host_organization_lineage":["https://openalex.org/P4360969325"],"host_organization_lineage_names":["Cognizant Communication Corporation"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.techscience.com/or/online/detail/28777/TSP_OR_88774.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5159613273","display_name":"Xiaojing Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaojing Liu","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159689305","display_name":"Beibei Hua","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Beibei Hua","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159652249","display_name":"Yang Xia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yang Xia","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101183031","display_name":"Huijie Huang","orcid":"https://orcid.org/0000-0002-1286-2252","observed_orcids":["https://orcid.org/0000-0002-1286-2252"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Huijie Huang","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159597796","display_name":"Areai Hakewati","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Areai Hakewati","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159646341","display_name":"Zeze Jin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zeze Jin","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159596652","display_name":"Tumaris Halifu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tumaris Halifu","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5159701392","display_name":"Zaihua Xu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Zaihua Xu","raw_affiliation_strings":["Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, The Friendship Hospital of Ili Kazakh Autonomous Prefecture, 58 Chongqing Road, Yining, Xinjiang Uygur Autonomous Region, China","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5159701392"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.85753298,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"34","issue":"11","first_page":"1","last_page":"10"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.9136000275611877,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.050599999725818634,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10146","display_name":"Cervical Cancer and HPV Research","score":0.023800000548362732,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/camrelizumab","display_name":"camrelizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/famitinib","display_name":"famitinib","score":1.0},{"id":"https://openalex.org/keywords/metastatic-cervical-cancer","display_name":"metastatic cervical cancer","score":0.8349999785423279},{"id":"https://openalex.org/keywords/recurrent-cervical-cancer","display_name":"recurrent cervical cancer","score":0.9549999833106995},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6639999747276306},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.8539999723434448},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.7020000219345093},{"id":"https://openalex.org/keywords/taxane-based-chemotherapy","display_name":"taxane-based chemotherapy","score":0.9739999771118164},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6340000033378601},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.7630000114440918},{"id":"https://openalex.org/keywords/clinical-outcomes","display_name":"clinical outcomes","score":0.6949999928474426},{"id":"https://openalex.org/keywords/safety-profile","display_name":"safety profile","score":0.6629999876022339}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8765000104904175},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7123000025749207},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6723999977111816},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6593000292778015},{"id":"https://openalex.org/C2778220009","wikidata":"https://www.wikidata.org/wiki/Q160105","display_name":"Cervical cancer","level":3,"score":0.5547999739646912},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5198000073432922},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.45419999957084656},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.42100000381469727},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4138000011444092},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4108000099658966},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.334199994802475},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3273000121116638},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3231000006198883},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.3005000054836273},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.29919999837875366},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.2678000032901764},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26759999990463257},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.2526000142097473},{"id":"https://openalex.org/C2779070825","wikidata":"https://www.wikidata.org/wiki/Q760434","display_name":"Augment","level":2,"score":0.2506999969482422}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D002583","descriptor_name":"Uterine Cervical Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.32604/or.2026.088774","doi":"https://doi.org/10.32604/or.2026.088774","is_oa":true,"landing_page_url":"https://doi.org/10.32604/or.2026.088774","pdf_url":"https://www.techscience.com/or/online/detail/28777/TSP_OR_88774.pdf","source":{"id":"https://openalex.org/S146643948","display_name":"Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics","issn_l":"0965-0407","issn":["0965-0407","1555-3906"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","medline","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4360969325","host_organization_name":"Cognizant Communication Corporation","host_organization_lineage":["https://openalex.org/P4360969325"],"host_organization_lineage_names":["Cognizant Communication Corporation"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology Research","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13732342","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13732342/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13732342/pdf/OncolRes-34-88774.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncol Res","raw_type":"Text"},{"id":"pmid:42985504","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42985504","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology research","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.32604/or.2026.088774","doi":"https://doi.org/10.32604/or.2026.088774","is_oa":true,"landing_page_url":"https://doi.org/10.32604/or.2026.088774","pdf_url":"https://www.techscience.com/or/online/detail/28777/TSP_OR_88774.pdf","source":{"id":"https://openalex.org/S146643948","display_name":"Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics","issn_l":"0965-0407","issn":["0965-0407","1555-3906"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","medline","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4360969325","host_organization_name":"Cognizant Communication Corporation","host_organization_lineage":["https://openalex.org/P4360969325"],"host_organization_lineage_names":["Cognizant Communication Corporation"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology Research","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223674945.pdf","grobid_xml":"https://content.openalex.org/works/W7223674945.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4411630472","https://openalex.org/W4403251063","https://openalex.org/W4387809628","https://openalex.org/W3088619449","https://openalex.org/W4311579551","https://openalex.org/W4403749103","https://openalex.org/W4413735122","https://openalex.org/W4379282011","https://openalex.org/W4411643008","https://openalex.org/W7129765415"],"abstract_inverted_index":{"Background:":[0],"Comparative":[1],"real-world":[2],"evidence":[3],"for":[4],"camrelizumab":[5],"plus":[6,11],"famitinib":[7],"versus":[8],"PD-1":[9],"inhibitor":[10],"platinum-":[12],"and/or":[13],"taxane-based":[14],"chemotherapy":[15],"with":[16],"or":[17,23],"without":[18],"bevacizumab":[19],"in":[20],"persistent,":[21],"recurrent,":[22],"metastatic":[24],"cervical":[25],"ca...":[26],"|":[27],"Find,":[28],"read":[29],"and":[30],"cite":[31],"all":[32],"the":[33],"research":[34],"you":[35],"need":[36],"on":[37],"Tech":[38],"Science":[39],"Press":[40]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-10-27T00:00:00"}